OKYO Pharma (OKYO) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for inflammatory eye diseases and ocular pain, with a lead candidate targeting neuropathic corneal pain (NCP) and dry eye disease (DED).

• Lead product, urcosimod, is a first-in-class chemerin receptor agonist designed for topical ocular use, with dual anti-inflammatory and pain-modulating mechanisms.

• Urcosimod has shown promising results in both preclinical models and early-stage clinical trials for NCP and DED.

• Holds exclusive licenses to key intellectual property supporting urcosimod and related programs.

Financial performance and metrics

• As of September 30, 2025, cash and cash equivalents were approximately $4.2 million.

• Received $1.9 million in non-dilutive funding in July 2025 to support R&D and clinical milestones.

• Cumulative carryforward tax losses of $35.85 million as of March 31, 2025.

• Independent auditor expressed substantial doubt about ability to continue as a going concern beyond July 2026 without improved liquidity.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, R&D, regulatory affairs, clinical trials, acquisitions, investments, and potential repayment or repurchase of debt or capital stock.

• Specific allocation and timing will depend on funding requirements and availability of other funds.